Hepatitis C

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on horizon

By

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

J&J logs $19.5B in Q2 sales

J&J logs $19.5B in Q2 sales

By

Hepatitis C medication Olysio was a star, but the company cautions competition is coming.

Vertex to submit CF drug combo to FDA this year

Vertex to submit CF drug combo to FDA this year

By

Phase III results showing improved lung function among cystic fibrosis patients using a combination of Kalydeco and lumacaftor means drugmaker Vertex is filing the two-part drug for FDA approval during the fourth quarter.

Oregon seeks HCV Rx waiver

The Oregon Health Plan wants to keep hep. C medications Sovaldi and Olysio off its list of covered treatments.

Medicare to cover some hep. C screening

Patients have to be high-risk or Baby Boomers for coverage.

Sovaldi Rx are being filled, despite payer angst

Sovaldi Rx are being filled, despite payer angst

By

Physicians tell Leerink most of their patients are receiving the drug. Rejections tend to be over off-label use.

Insurers struggle with Sovaldi angst

A report indicates that Sovaldi's high price may hurt health-insurance investors.

Merck adds heat to HCV competition

Merck adds heat to HCV competition

By

Phase-II data show reduced hepatitis-C RNA levels among HIV-positive patients, the drugmaker shared at a medical meeting. Boehringer also released co-infection data.

AbbVie's all-oral HCV combo shines in trial

AbbVie's all-oral HCV combo shines in trial

By

Data presented at a conference yesterday suggest AbbVie's all-oral regimen may be more effective than Gilead's at curing the virus in certain patients, but will it confer an edge?

Email Newsletters